| Dr Donna Lynn Eskwitt, PHD | |
|
1867 California Ave Ste 101, Corona, CA 92881-7281 | |
| (714) 692-2270 | |
| Not Available |
| Full Name | Dr Donna Lynn Eskwitt |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 1867 California Ave Ste 101, Corona, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205975513 | NPI | - | NPPES |
| 700 | Other | CA | AUDIOLOGY LICENSE |
| 030814 | Other | OR | AUDIOLOGY LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AU700 (California) | Secondary |
| 237600000X | Audiologist-hearing Aid Fitter | AU700 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donna Lynn Eskwitt, PHD 73061 Joshua Tree St, Palm Desert, CA 92260-4772 Ph: (760) 902-0922 | Dr Donna Lynn Eskwitt, PHD 1867 California Ave Ste 101, Corona, CA 92881-7281 Ph: (714) 692-2270 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.
A new study raises the possibility of modulating asthma symptoms via the bacteria that commonly live in the upper airway. The work, which was published on December 16, 2019, in the journal Nature Communications, shows that in children who have mild to moderate asthma, the microbiome of the upper airway could determine how severe the symptoms are.
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.
A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.
› Verified 2 days ago